Fig. 2From: Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in ThailandOverall survival of patients receiving adjuvant imatinib after surgery obtaining from the model and from the RCTBack to article page